Back to results
US 2022/0089724 A1Published application
Treatment of neurotoxicity and/or cytokine release syndrome
AssigneeAutolus Limited
InventorVijay Peddareddigari
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of an IL-1β inhibitor for the prevention and/or treatment of neurotoxicity and/or cytokine release syndrome in a subject undergoing immunotherapy, wherein the IL-1β inhibitor is administered before immunotherapy.
Claims21
1-26. (canceled)
A method of prevention and/or treatment of neurotoxicity and/or cytokine release syndrome in a human subject undergoing immunotherapy, the method comprising administering to a human subject in need thereof an IL-1β inhibitor before immunotherapy.
Dependencies are inferred from the claim text.